Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM64PM7)

Drug Name
EXO-230 Drug Info
Synonyms GLY-230
Indication
Disease Entry ICD 11 Status REF
Diabetic neuropathy 8C0Z Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DM64PM7

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 1 (COX-1) TT8NGED PGH1_HUMAN Agonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Prostaglandin G/H synthase 1 (COX-1) DTT PTGS1 6.09 7.747 6.04 7.023
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Diabetic neuropathy
ICD Disease Classification 8C0Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin G/H synthase 1 (COX-1) DTT PTGS1 3.97E-03 0.16 0.43
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00544934) Multiple Dose Trial of Anti-glycation Agent GLY-230 in Healthy and Diabetic Subjects. U.S. National Institutes of Health.
2 Inhibiting Amadori-modified albumin formation improves biomarkers of podocyte damage in diabetic rats. Physiol Rep. 2013 September; 1(4): e00083.